Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Possible implications for choice of MRD method, timing of MRD monitoring, and guidance of therapy are discussed in general and in some detail for certain types of leukemia with specific molecular markers to monitor, including core binding factor (CBF)-leukemias and NPM1-mutated leukemias.
|
30919505 |
2019 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Up-regulation of EMT-related gene VCAN by NPM1 mutant-driven TGF-β/cPML signalling promotes leukemia cell invasion.
|
31777586 |
2019 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nucleophosmin in leukemia: Consequences of anchor loss.
|
31009764 |
2019 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nucleophosmin(NPM1)-mutated protein, a leukemia-specific antigen, represents an ideal target for AML immunotherapy.
|
30783516 |
2019 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, different mechanisms would orchestrate the dysregulation of NPM function in NPMc+- versus NPM1-MLF1-associated leukemia.
|
31675375 |
2019 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The levels of the particular NPM1 transcripts were significantly different but highly correlated with each other in both leukemia and control samples.
|
30126426 |
2018 |
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By analyzing the enrichment of differentially‑expressed genes in chemical and genetic perturbation datasets, it was found that genes, which were upregulated in the FLT3 high expression group had myeloid lymphoid leukemia‑ and nucleophosmin 1‑like signatures, indicating that the overexpression of FLT3 may use the same mechanism to promote leukemia.
|
29257272 |
2018 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, miR-10a/b overexpression was not associated with complete remission rate, and did not have an impact on both leukemia free survival and overall survival time in non-M3 AML patients without NPM1 mutation.
|
29254789 |
2018 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results indicate that INPP4B promotes leukemia cell survival via SGK3 activation, and INPP4B might be a potential target in the treatment of NPM1-mutated AML.
|
29343273 |
2018 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Areas covered: Available techniques include multi-color flow cytometry (MFC) of leukemia associated immunophenotypes (LAIP), quantitative reverse transcriptase polymerase chain reaction (QRT-PCR) for detecting fusion and mutated genes (RUNX1-RUNX1T1, CBFB-MYH11, and NPM1), overexpression of genes such as WT1, and next generation sequencing (NGS) for MRD.
|
28475434 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, EAPB0503 selectively reduced the leukemia burden in NPM1c AML xenograft mice.
|
28055106 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
AML with mutated nucleophosmin (NPM1) is regarded as an independent leukemia subtype.
|
29441887 |
2017 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conformational stabilization as a strategy to prevent nucleophosmin mislocalization in leukemia.
|
29066752 |
2017 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
|
27535106 |
2016 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated leukemia-associated immunophenotypes (LAIP) and their correlation with fms-like tyrosine kinase 3 (FLT3) and nucleophosmin (NPM1) gene mutational status in order to contribute a better identification of patients at highest risk of relapse in acute myeloid leukemia (AML).
|
25957287 |
2015 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Leukemia-Associated Mutations in Nucleophosmin Alter Recognition by CRM1: Molecular Basis of Aberrant Transport.
|
26091065 |
2015 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that circulating NPM mutations DNA assay serves as a complementary to the routine investigative protocol of NPM-mutated leukemia.
|
25552914 |
2015 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Skewed cytoplasmic accumulation of NPM mutant protein (NPM1c+) is close related to leukemia pathogenesis.
|
24902788 |
2014 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that while K-RAS mutations are infrequent in CN-AML, activating K-RAS mutations may cooperate with mutated NPM1 to induce leukemia.
|
24737308 |
2014 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we focus on the leukemia-associated NPM1 C-terminal domain and describe its structure, function, and the effect exerted by leukemic mutations.
|
23436734 |
2013 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the role of NPM in drug-resistance of leukemia has not yet been explored.
|
23669237 |
2013 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
|
22766221 |
2012 |
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Altogether, these pieces of evidence point to NPM1-mutated AML as a founder genetic event that defines a distinct leukemia entity accounting for approximately one-third of all AML.
|
21030560 |
2011 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, little is known about the role of NPM1 in leukemia.
|
21537492 |
2011 |
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the presence of mutations in the points most frequent for mutations (hotspot mutations) in phosphatidylinositol-3-kinase (PI3K), Janus kinase 2 (JAK2), FMS-like tyrosine kinase 3 (FLT3) and nucleophosmin (NPM1), which are involved in leukemia and other cancers, in a population of Brazilian MDS patients.
|
21789382 |
2011 |